The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

However, the research so far has identified how an infant’s immune system can be hostile to preleukemic cells, and most ...

Tracing the Shared Roots of Lymphoblastic Lymphoma and Leukemia ...

A groundbreaking study has uncovered molecular markers in blood at birth that are linked to later development of acute ...

IN A breakthrough study, researchers have reported encouraging outcomes using autologous chimeric antigen receptor (CAR) T ...

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic ...

The development of CAR-T technology in recent years has been a major milestone in the fight against cancer. These sort of "living drugs"—T-cells modified to expand, recognize and attack cancer ...